It was reported yesterday that the collaboration is aimed at facilitating greater visibility and deeper investment in advancing dystonia and Parkinson's research. It establishes a major dystonia research prize to expand public awareness, acknowledge key scientific discoveries and incentivise the work of dedicated researchers in dystonia, an under-funded movement disorder and an under-recognised symptom of Parkinson's disease.
Bonnie Strauss, founder and president of The Bachmann-Strauss Dystonia and Parkinson Foundation, said, 'Our foundation has always served a dual mission of funding research to find better treatments for both dystonia and Parkinson's. By aligning with MJFF now and taking on this new role, we have opportunities to make an even greater impact and generate more awareness for dystonia on a much larger and brighter stage.'
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia